2011
The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories
Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D’Souza D, The Yale THC Study Group. The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 2011, 219: 885-896. PMID: 21845389, DOI: 10.1007/s00213-011-2417-y.Peer-Reviewed Original ResearchConceptsAdverse eventsPost-study periodCareful subject selectionMinor adverse eventsPhysical adverse eventsFrequent side effectsLong-term followCannabinoid receptor systemFaster infusion rateCannabinoid receptor ligandsIntravenous THCPlacebo infusionCannabinoid systemInfusion rateStudy participationSide effectsAbuse liabilityHigh dosesReceptor systemΔ9-tetrahydrocannabinolInfusionPsychoactive effectsReceptor ligandsTest daySubjects
2009
GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression
Esterlis I, Cosgrove KP, Batis JC, Bois F, Kloczynski TA, Stiklus SM, Perry E, Tamagnan GD, Seibyl JP, Makuch R, Krishnan‐Sarin S, O'Malley S, Staley JK. GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression. Synapse 2009, 63: 1089-1099. PMID: 19642218, PMCID: PMC2778224, DOI: 10.1002/syn.20688.Peer-Reviewed Original ResearchConceptsSpielberger State-Trait Anxiety IndexState-Trait Anxiety IndexDepressive symptomsSubsyndromal anxietyAnxiety symptomsPain toleranceReceptor availabilityAbstinent tobacco smokersSex-matched nonsmokersSingle photon emissionPain symptomsHealthy ageSmoking statusTobacco smokersSubsyndromal depressionAbstinent smokersVulnerable smokersCold pressor taskNonsmokersGamma-aminobutyricEpidemiology ScaleSmokersAcute abstinenceBrain areasSymptoms
2004
The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis
D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology 2004, 29: 1558-1572. PMID: 15173844, DOI: 10.1038/sj.npp.1300496.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnxietyArousalAttentionBehaviorCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolFemaleHallucinogensHemodynamicsHumansHydrocortisoneInjections, IntravenousMaleMemory, Short-TermMental RecallPanicProlactinPsychiatric Status Rating ScalesPsychometricsPsychoses, Substance-InducedSpeechVerbal LearningConceptsCannabinoid receptor functionWord recallRecognition recallVerbal fluencyCognitive deficitsProspective safety dataNegative symptomsAbuse disordersHealthy individualsCounterbalanced studyMonths poststudyRecallPsychotomimetic effectsPsychotic disordersReceptor functionPsychosisEndogenous psychosesIndividualsDistractibilityFluencyTransient symptomsDisordersEndocrine effectsSafety dataAnxiety